You are here

P&T® Journal contents for August 2004

Features

Meeting Highlights
The author outlines recent advances in the treatment of cancers of the brain, breast, colon, prostate gland, lung, and blood.
Lawrence M. Prescott, PhD
In the authors’ study of more than 4,000 veterans with diabetes, prescribing patterns, monthly total costs, and control of blood glucose levels differed according to hospital site. The authors show the relationships between the type of primary care provider, the intensity of treatment, monthly medication costs, monthly total costs, and glycemic control.
Shawn L. Fultz, MD, MPH, C. Bernie Good, MD, MPH, Mary E. Kelley, MS, and Michael J. Fine, MD, MSc
The author reviews a combination tablet for lowering cholesterol (Vytorin™™), a new use for botulinum toxin (Botox®) for severe underarm sweating, and levofloxacin (Levaquin®) for patients with multidrug-resistant strains of Streptococcus pneumoniae in community-acquired pneumonia.
Marvin M. Goldenberg, PhD, RPh, MS
Linezolid (Zyvox®), an oral antimicrobial agent, appears to be safe and effective for treating moderately severe cases of cellulitis.
Gary E. Stein, PharmD, Sharon Schooley, Vivek Kak, MD, and Daniel H. Havlichek, MD
Continuing Medical Education
Dr. Lin and Dr. English discuss some new approaches to the therapy for a rare skin condition.
Peggy Lin, MD, and Joseph C. English III, MD

Departments

Editorial
David Nash, MD, MBA, explains how the adverse effects of second-generation (atypical) antipsychotic agents represent a conundrum for P&T committee members.
David Nash, MD, MBA
Medication Errors
Matthew Grissinger, RPh, FASCP, offers some solutions for resolving conflicts in drug therapy.
Matthew Grissinger, RPh, FASCP
Prescription: Washington
Stephen Barlas discusses a “drug lottery program,” part of the Medicare Modernization Act of 2003, which is intended to help some beneficiaries with their prescription drug costs.
Stephen Barlas
P&T presents the latest information about FDA approvals, drug indications, industry updates, and new devices.
Drug Forecast
The authors review tiotropium bromide (Spiriva®) for the treatment of chronic obstructive pulmonary disease.
Michelle Levinzon, PharmD, and Larisa Chagan, BS, PharmD, BCPS